Danaher Scoops Up Aldevron In $9.6B Deal

Danaher Corporation (NYSE:DHR) has agreed to acquire privately-held Aldevron for a cash purchase price of approximately $9.6 billion.
Danaher expects to finance the acquisition using cash on hand or proceeds from the issuance of commercial paper.
Founded in 1998, Aldevron manufactures plasmid DNA, mRNA, and proteins, serving biotechnology and pharmaceutical customers across research, clinical and commercial applications.
It employs around 600 people.
Aldevron will operate as a standalone operating company and brand within Danaher's Life Sciences segment.
Price Action: DHR shares closed at $244.74 on Wednesday.